These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 34497589

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF, Kushner P, Aguilar R.
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [Abstract] [Full Text] [Related]

  • 3. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J, Gallwitz B.
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [Abstract] [Full Text] [Related]

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q.
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.
    Dave BP, Chorawala MR, Shah IV, Shah NN, Bhagat SU, Prajapati BG, Thakkar PC.
    Mol Biol Rep; 2024 Jul 23; 51(1):835. PubMed ID: 39042283
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM, Premkumar B, Prabhawathi V, Prabhakar PK.
    Mini Rev Med Chem; 2021 Jul 23; 21(20):3166-3182. PubMed ID: 33888049
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
    Heuvelman VD, Van Raalte DH, Smits MM.
    Cardiovasc Res; 2020 Apr 01; 116(5):916-930. PubMed ID: 31825468
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK.
    Cardiovasc Diabetol; 2018 Dec 13; 17(1):157. PubMed ID: 30545359
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.